Literature DB >> 8905029

Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center.

P Soubeyran1, H Eghbali, M Trojani, F Bonichon, P Richaud, B Hoerni.   

Abstract

BACKGROUND: A wait-and-see policy (WS) does not appear to modify the long-term prognosis of advanced-stage follicular lymphomas (FL), while irradiation of limited stages sometimes causes complications and does not avert distant relapses. Consequently, we decided to test WS in a selected subset of the localized FL, i.e., patients in complete remission (CR) after the initial lymph node biopsy (stage I0). PATIENTS AND METHODS: Forty-three previously untreated patients were diagnosed with stage I0 FL and 26 of them were included in the WS. Their median age was 60.3 years; 19 were male and 24 female. All histological slides were reviewed and confirmed the diagnosis of FL. Median follow-up was 6.3 years (y).
RESULTS: Thirteen of the 26 untreated patients are still relapse-free, while six relapsed locally only (median: 4.2 years after diagnosis), and reattained CR with radiotherapy. Seven patients relapsed at distant sites (median: 1 year after diagnosis). No localized relapses were observed in the treated group, but there were 7 distant relapses.
CONCLUSIONS: The use of WS in stage I0 FL did not appear to modify the prognosis of these patients. Furthermore, we observed two distinct patterns of relapse (local and distant) that are difficult to differentiate at onset.

Entities:  

Mesh:

Year:  1996        PMID: 8905029     DOI: 10.1093/oxfordjournals.annonc.a010720

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  11 in total

Review 1.  Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?

Authors:  Brian K Link
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

2.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).

Authors:  M Ghielmini; U Vitolo; E Kimby; S Montoto; J Walewski; M Pfreundschuh; M Federico; P Hoskin; C McNamara; F Caligaris-Cappio; S Stilgenbauer; R Marcus; M Trneny; P Dreger; E Montserrat; M Dreyling
Journal:  Ann Oncol       Date:  2012-11-21       Impact factor: 32.976

3.  Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?

Authors:  Antonio Rueda; María Casanova; Maximino Redondo; Elisabeth Pérez-Ruiz; Angeles Medina-Pérez
Journal:  BMC Cancer       Date:  2012-05-31       Impact factor: 4.430

4.  Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years.

Authors:  Dlawer Abdulla Barzenje; Milada Cvancarova Småstuen; Knut Liestøl; Alexander Fosså; Jan Delabie; Arne Kolstad; Harald Holte
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

Review 5.  Limited Stage Follicular Lymphoma: Current Role of Radiation Therapy.

Authors:  Andrea Riccardo Filippi; Patrizia Ciammella; Umberto Ricardi
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-09-01       Impact factor: 2.576

6.  Incidental finding of lymphoma after septoplasty.

Authors:  Edward C Kuan; Bobby A Tajudeen; Sunita M Bhuta; Miguel Fernando Palma Diaz; Paul A Kedeshian; Jeffrey D Suh
Journal:  Allergy Rhinol (Providence)       Date:  2016-07-27

Review 7.  How we treat mature B-cell neoplasms (indolent B-cell lymphomas).

Authors:  Melissa Lumish; Lorenzo Falchi; Brandon S Imber; Michael Scordo; Gottfried von Keudell; Erel Joffe
Journal:  J Hematol Oncol       Date:  2021-01-06       Impact factor: 17.388

Review 8.  Time for an individualized approach to first-line management of follicular lymphoma.

Authors:  Guillaume Cartron; Judith Trotman
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

9.  Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?

Authors:  Anne-Sophie A S Michallet; Laure L Lebras; Deborah D Bauwens; Fadhela F Bouafia-Sauvy; Françoise F Berger; Christelle C Tychyj-Pinel; Anne A D'Hombres; Gilles G Salles; Bertrand B Coiffier
Journal:  J Hematol Oncol       Date:  2013-07-01       Impact factor: 17.388

10.  Rapidly progressed primary intestinal follicular lymphoma with elevation of soluble interleukin-2 receptor levels.

Authors:  Masaya Iwamuro; Ryuta Takenaka; Atsushi Mori; Shigeatsu Fujiki; Takayoshi Miyake; Shoji Asakura; Hiroyuki Okada; Katsuyoshi Takata; Tadashi Yoshino; Kazuhide Yamamoto
Journal:  Case Rep Oncol Med       Date:  2014-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.